{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:26:26Z","timestamp":1788629186768,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008963","name":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012118","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012118","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012665","name":"Institute for Clinical Evaluative Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013873","name":"Government of Ontario","doi-asserted-by":"publisher","award":["-035"],"award-info":[{"award-number":["-035"]}],"id":[{"id":"10.13039\/100013873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004203","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001350","name":"Ministry of Health -Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.eclinm.2024.102443","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T18:53:56Z","timestamp":1707764036000},"page":"102443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1692-1125","authenticated-orcid":false,"given":"Alberto","family":"Hernando-Calvo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe L.","family":"Bedard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin K.W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy R.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Weymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-525X","authenticated-orcid":false,"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean A.","family":"Regier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishal","family":"Gyawali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Kain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C.","family":"Earle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albiruni R.","family":"Abdul Razak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanrudee","family":"Isaranuwatchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sabatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L.","family":"Stockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor J.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian L.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3228-6042","authenticated-orcid":false,"given":"Timothy P.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.eclinm.2024.102443_bib1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41571-021-00501-4","article-title":"Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer","volume":"18","author":"Chaft","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102443_bib2","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc2031965","article-title":"The spectrum of benefit from checkpoint blockade in hypermutated tumors","volume":"384","author":"Rousseau","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102443_bib3","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jval.2023.07.004","article-title":"Toward best practices for economic evaluations of tumor-agnostic therapies: a review of current barriers and solutions","volume":"26","author":"Weymann","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.eclinm.2024.102443_bib4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/PO.19.00398","article-title":"Evolving landscape of molecular prescreening strategies for oncology early clinical trials","volume":"4","author":"Dienstmann","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102443_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular profiling for precision cancer therapies","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Med"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102443_bib6","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.3747\/co.26.5235","article-title":"OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharing","volume":"26","author":"Malone","year":"2019","journal-title":"Curr Oncol"},{"issue":"29_suppl","key":"10.1016\/j.eclinm.2024.102443_bib7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2020.38.29_suppl.283","article-title":"An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors","volume":"38","author":"Saleh","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102443_bib8","series-title":"Cost-consequences analysis - an underused method of economic evaluation","author":"Hunter","year":"2005"},{"key":"10.1016\/j.eclinm.2024.102443_bib9","series-title":"Guidelines on Person-Level Costing Using Administrative Databases in Ontario","author":"Wodchis","year":"2013"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102443_bib10","doi-asserted-by":"crossref","first-page":"e807","DOI":"10.1200\/JOP.18.00691","article-title":"Can administrative data improve the performance of cancer clinical trial economic analyses?","volume":"15","author":"Hanna","year":"2022","journal-title":"J\u00a0Oncol Pract"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102443_bib11","doi-asserted-by":"crossref","first-page":"E191","DOI":"10.9778\/cmajo.20190114","article-title":"Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study","volume":"8","author":"Mittmann","year":"2020","journal-title":"CMAJ Open"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102443_bib12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3747\/co.26.5279","article-title":"The generation of two specific cancer costing algorithms using Ontario administrative databases","volume":"26","author":"Mittmann","year":"2019","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102443_bib13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamainternmed.2014.1001","article-title":"Use of chemotherapy within the last 14 Days of life in patients treated at a comprehensive cancer center","volume":"174","author":"Rodriguez","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102443_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3747\/co.22.2636","article-title":"Quality of end-of-life cancer care in Canada: a retrospective four-province study using administrative health care data","volume":"22","author":"Barbera","year":"2015","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102443_bib16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102443_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J\u00a0Roy Stat Soc B"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102443_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.eclinm.2024.102443_bib19","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102443_bib31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12687-021-00557-w","article-title":"Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care","volume":"13","author":"Weymann","year":"2022","journal-title":"J Commun Genet"},{"key":"10.1016\/j.eclinm.2024.102443_bib20","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/PO.20.00540","article-title":"Budget impact analysis of comprehensive genomic profiling in patients with advanced non\u2013small-cell lung cancer","volume":"5","author":"Harvey","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102443_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/ejh.13899","article-title":"Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials: a study based on the EORTC-Dutch late effects cohort-linked data","volume":"110","author":"Juul","year":"2023","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.eclinm.2024.102443_bib22","first-page":"1","article-title":"End-of-life care quality measures: beyond place of death","author":"Hoare","year":"2022","journal-title":"BMJ Support Palliat Care"},{"issue":"26","key":"10.1016\/j.eclinm.2024.102443_bib23","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102443_bib24","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2024.102443_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2022.09.005","article-title":"Access and quality of biomarker testing for precision oncology in Europe","volume":"176","author":"Normanno","year":"2022","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102443_bib26","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.3390\/curroncol29100572","article-title":"Precision oncology in Canada: converting vision to reality with lessons from international programs","volume":"29","author":"Liu","year":"2022","journal-title":"Curr Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102443_bib27","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102443_bib28","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","article-title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) \u226510: a decision centered on empowering patients and their physicians","volume":"31","author":"Subbiah","year":"2020","journal-title":"Ann Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:39:21Z","timestamp":1781642361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024000221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":28,"alternative-id":["S2589537024000221"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102443","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102443"}}